Bioregenx (BRGX) Capital Expenditures (2024 - 2025)

Bioregenx (BRGX) posted quarterly Capital Expenditures of $3057.0 for Q4 2025, down 49.05% quarter-over-quarter from $6000.0 in Q3 2025.

Bioregenx (BRGX) Capital Expenditures (2024 - 2025) Analysis & Trends

Bioregenx's Capital Expenditures history runs 2 years deep, the most recent figure standing at $3057.0 for Q4 2025.

In Q4 2025, Capital Expenditures changed N/A year-over-year to $3057.0; the TTM figure through Dec 2025 stood at $9057.0 (down 95.22% YoY), while the FY2025 annual figure was $9057.0, down 95.22% from the prior year.
Capital Expenditures for Q4 2025 stood at $3057.0, down from $6000.0 in the prior quarter.
The five-year high for Capital Expenditures was $189390.0 in Q1 2024, with the low at $3057.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	1.75 Mn
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	29.03 Mn
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	15.93 Mn
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	1.59 Mn
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	1.73 Mn
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	56.00 Mn
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	16.11 Mn
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	2.32 Mn
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	-
10	Bioregenx	9.72 Mn	9.67 Mn	348,288.00	-

Download Data